The authors would like to acknowledge all members of the IR-Tox team who contributed to the care of the patients included in this manuscript, and those who referred patients to this pilot program. We extend special thanks to the team members who were not included as co-authors but contributed to the development of this manuscript: Jennifer Mammen, MD; Inbal Sander MD; Joanna Melia, MD; Lyle Ostrow, MD, PhD; Meghan Berkenstock, MD; Alan Baer, MD; Lonny Yarmus, DO; Patricia Brothers, BSN; Anna Ferguson, BSN; Maureen Berg, BSN; Dung T. Le, MD; Kristen A. Marrone, MD; Leisha A. Emens, MD, PhD; William J. Sharfman, MD; and Elizabeth M. Jaffee, MD, PhD.
Lee BKim KChoi JY. Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: a prospective study. Medicine (Baltimore) 2017;96:e8089.
Wheless SAMcKinney KAZanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg 2010;143:650–654.
van Hagen PSpaander MCvan der Gaast A. Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study. Int J Clin Oncol 2013;18:214–219.
Kurpad RKim WRathmell WK. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Urol Oncol 2011;29:378–382.
Schmidt HMRoberts JMBodnar AM. Thoracic multidisciplinary tumor board routinely impacts therapeutic plans in patients with lung and esophageal cancer: a prospective cohort study. Ann Thorac Surg 2015;99:1719–1724.
van der Velden DLvan Herpen CMvan Laarhoven HW. Molecular tumor boards: current practice and future needs. Ann Oncol 2017;28:3070–3075.
Postow MASidlow RHellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–168.
Gupta ADe Felice KMLoftus EV Jr. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015;42:406–417.
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed August 24 2018.
Wolchok JDChiarion-Sileni VGonzalez R. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377:1345–1356.
Hellmann MDCiuleanu TEPluzanski A. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378:2093–2104.
Motzer RJTannir NMMcDermott DF. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277–1290.
Antonia SJLópez-Martin JABendell J. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883–895.
Neelapu SSTummala SKebriaei P. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47–62.
Zhou CCrawford ASerhal E. The impact of Project ECHO on participant and patient outcomes: a systematic review. Acad Med 2016;91:1439–1461.
Lisberg ATucker DAGoldman JW. Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center. Cancer Immunol Res 2018;6:288–294.